Table 4 Efficacy findings for paliperidone ER and risperidone dose groups (change from baseline to end point)
From: Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
Paliperidone ER 6-12 mg/day n = 179 | Risperidone 2-4 mg/day n = 113 | Risperidone 4-6 mg/day n = 126* | Pooled Placebo n = 186* | |
|---|---|---|---|---|
PANSS | ||||
Total score, adjusted mean change (SE) | -18.4 (1.7) | -11.6 (2.2) | -18.7 (2.0) | -6.4 (1.7) |
Mean difference (estimated SE)† | ||||
Active-PBO | -12.0 (2.4)‡ | -5.4 (2.8) | -12.0 (2.6)‡ | NA |
PALI-RIS 2-4 mg | -6.7 (2.8)§ | NA | NA | NA |
PALI-RIS 4-6 mg | 0.2 (2.6) | NA | NA | NA |
Negative factor, adjusted mean change (SE) | -4.7 (0.5) | -2.5 (0.6) | -3.8 (0.5) | -2.1 (0.4) |
Mean difference (estimated SE)† | ||||
Active-PBO | -2.6 (0.6)‡ | -0.5 (0.8) | -1.7 (0.7)§ | NA |
PALI-RIS 2-4 mg | -2.1 (0.8)§ | NA | NA | NA |
PALI-RIS 4-6 mg | -0.9 (0.7) | NA | NA | NA |
Positive factor, adjusted mean change (SE) | -6.2 (0.5) | -4.5 (0.7) | -6.3 (0.7) | -2.3 (0.5) |
Mean difference (estimated SE)† | ||||
Active-PBO | -4.0 (0.8)‡ | -2.2 (0.9)§ | -4.1 (0.8)‡ | NA |
PALI-RIS 2-4 mg | -1.7 (0.9) | NA | NA | NA |
PALI-RIS 4-6 mg | 0.1 (0.8) | NA | NA | NA |
Anxiety/depression, adjusted mean change (SE) | -2.3 (0.3) | -1.7 (0.3) | -2.5 (0.3) | -1.4 (0.3) |
Mean difference (estimated SE)† | ||||
Active-PBO | -0.9 (0.4)§ | -0.3 (0.4) | -1.1 (0.4) § | NA |
PALI-RIS 2-4 mg | -0.6 (0.4) | NA | NA | NA |
PALI-RIS 4-6 mg | 0.2 (0.4) | NA | NA | NA |
Disorganized thoughts, adjusted mean change (SE) | -3.5 (0.4) | -2.3 (0.5) | -4.2 (0.5) | -1.1 (0.4) |
Mean difference (estimated SE)† | ||||
Active-PBO | -2.4 (0.6)‡ | -1.3 (0.7) | -3.2 (0.7)‡ | NA |
PALI-RIS 2-4 mg | -1.1 (0.7) | NA | NA | NA |
PALI-RIS 4-6 mg | 0.8 (0.7) | NA | NA | NA |
Uncontrolled hostility/excitement, adjusted mean change (SE) | -1.4 (0.3) | -0.6 (0.4) | -2.0 (0.4) | 0.6 (0.3) |
Mean difference (estimated SE)† | ||||
Active-PBO | -2.0 (0.5)‡ | -1.2 (0.5)§ | 2.6 (0.5)‡ | NA |
PALI-RIS 2-4 mg | -0.8 (0.5) | NA | NA | NA |
PALI-RIS 4-6 mg | 0.6 (0.5) | NA | NA | NA |
CGI-S, adjusted mean change (SE) ¶ | -0.9 (0.1) | 0.0 (0.2) | -0.1 (0.2) | -0.2 (0.1) |
Mean difference (estimated SE)† | ||||
Active-PBO | -0.7 (0.1)‡ | 0.2 (0.2) | 0.0 (0.3) | NA |
PALI-RIS 2-4 mg | -0.9 (0.2)‡ | NA | NA | NA |
PALI-RIS 4-6 mg | -0.8 (0.3)§ | NA | NA | NA |
Response, % # | 55.1 | 40.7 | 51.6 | 28.1 |
Active-PBO | 26.9§ | 28.5§ | 23.4§ | NA |
PALI-RIS 2-4 mg | 14.4§ | NA | NA | NA |
PALI-RIS 4-6 mg | 3.5 | NA | NA | NA |